Paolo Bonvini
Directorate-General for Interpretation(BE)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Sarcoma Diagnosis and Treatment, Acute Myeloid Leukemia Research, Ubiquitin and proteasome pathways, Chronic Myeloid Leukemia Treatments
Most-Cited Works
- → Bortezomib-mediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma(2007)185 cited
- → Identification of Ellagic Acid as Potent Inhibitor of Protein Kinase CK2: A Successful Example of a Virtual Screening Application(2006)150 cited
- → Regulation of leukemic cell adhesion, proliferation, and survival by β-catenin(2002)132 cited
- Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.(2002)
- → Ubiquitination and Proteasomal Degradation of Nucleophosmin-Anaplastic Lymphoma Kinase Induced by 17-Allylamino-Demethoxygeldanamycin(2004)92 cited
- → The measurement of ubiquitin and ubiquitinated proteins(1999)83 cited
- Geldanamycin abrogates ErbB2 association with proteasome-resistant beta-catenin in melanoma cells, increases beta-catenin-E-cadherin association, and decreases beta-catenin-sensitive transcription.(2001)
- → Inducible Hsp70 in the Regulation of Cancer Cell Survival: Analysis of Chaperone Induction, Expression and Activity(2011)71 cited
- → Urolithin as a Converging Scaffold Linking Ellagic acid and Coumarin Analogues: Design of Potent Protein Kinase CK2 Inhibitors(2011)59 cited
- → In vivo degradation of N-myc in neuroblastoma cells is mediated by the 26S proteasome(1998)57 cited